GANX Valuation

Gain Therapeutics Inc

Add to Watchlist

Advanced Chart

1.990

+0.11(5.851%)1D

Overview
Forecast
Valuation
Earnings

GANX Relative Valuation

GANX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GANX is overvalued; if below, it's undervalued.

Historical Valuation

Gain Therapeutics Inc (GANX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.10. The fair price of Gain Therapeutics Inc (GANX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.99 USD , Gain Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.99

Fair

Undervalued

-2.91

Trailing

Forward

0.00

EV/EBITDA

Gain Therapeutics Inc. (GANX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.52

EV/EBIT

Gain Therapeutics Inc. (GANX) has a current EV/EBIT of -2.52. The 5-year average EV/EBIT is -1.74. The thresholds are as follows: Strongly Undervalued below -4.78, Undervalued between -4.78 and -3.26, Fairly Valued between -0.22 and -3.26, Overvalued between -0.22 and 1.30, and Strongly Overvalued above 1.30. The current Forward EV/EBIT of -2.52 falls within the Historic Trend Line -Fairly Valued range.

0.00

Gain Therapeutics Inc. (GANX) has a current PS of 0.00. The 5-year average PS is 2567.30. The thresholds are as follows: Strongly Undervalued below -13020.28, Undervalued between -13020.28 and -5226.49, Fairly Valued between 10361.09 and -5226.49, Overvalued between 10361.09 and 18154.88, and Strongly Overvalued above 18154.88. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.71

P/OCF

Gain Therapeutics Inc. (GANX) has a current P/OCF of -3.71. The 5-year average P/OCF is -2.49. The thresholds are as follows: Strongly Undervalued below -8.49, Undervalued between -8.49 and -5.49, Fairly Valued between 0.51 and -5.49, Overvalued between 0.51 and 3.50, and Strongly Overvalued above 3.50. The current Forward P/OCF of -3.71 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Gain Therapeutics Inc. (GANX) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.94. The thresholds are as follows: Strongly Undervalued below -6.23, Undervalued between -6.23 and -4.09, Fairly Valued between 0.20 and -4.09, Overvalued between 0.20 and 2.35, and Strongly Overvalued above 2.35. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Gain Therapeutics Inc (GANX) has a current Price-to-Book (P/B) ratio of 16.57. Compared to its 3-year average P/B ratio of 5.01 , the current P/B ratio is approximately 230.62% higher. Relative to its 5-year average P/B ratio of 4.08, the current P/B ratio is about 306.42% higher. Gain Therapeutics Inc (GANX) has a Forward Free Cash Flow (FCF) yield of approximately -26.82%. Compared to its 3-year average FCF yield of -38.17%, the current FCF yield is approximately -29.73% lower. Relative to its 5-year average FCF yield of -31.28% , the current FCF yield is about -14.26% lower.

16.57

P/B

Median3y

5.01

Median5y

4.08

-26.82

FCF Yield

Median3y

-38.17

Median5y

-31.28

Competitors Valuation Multiple

The average P/S ratio for GANX's competitors is 13.76, providing a benchmark for relative valuation. Gain Therapeutics Inc Corp (GANX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GANX.O

Gain Therapeutics Inc

Insight Molecular Diagnostics Inc

Unicycive Therapeutics Inc

0.68

74.00M

PMVP.O

PMV Pharmaceuticals Inc

Loss

74.19M

Performance Decomposition

Market capitalization of GANX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GANX in the past 1 year is driven by Unknown.